Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients.

Torrente-Segarra, Vicenç; Fernández Prada, Manuel; Expósito, Rosa; Garrido Puñal, Noemí Patricia; Sánchez-Andrade, Amalia; Lamúa-Riazuelo, José Ramón; Olivé, Alejandro; Tovar, Juan Víctor; RENACER Study Group

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/55719

Title:	Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients.
Authors:	Torrente-Segarra, Vicenç Fernández Prada, Manuel Expósito, Rosa Garrido Puñal, Noemí Patricia Sánchez-Andrade, Amalia Lamúa-Riazuelo, José Ramón Olivé, Alejandro Tovar, Juan Víctor RENACER Study Group View more
Issue Date:	28-Jan-2019
Citation:	Reumatol Clin (Engl Ed).2021;(17)1:57-58
PMID:	30704922
URI:	https://hdl.handle.net/20.500.12530/55719
Appears in Collections:	Fundaciones e Institutos de Investigación > FIIB H. U. Infanta Sofía y H. U. Henares > Artículos

Files in This Item:

The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.

Show full item record